Cutter & CO Brokerage Inc. Has $118,000 Position in Amarin Co. plc (NASDAQ:AMRN)

Cutter & CO Brokerage Inc. lessened its stake in shares of Amarin Co. plc (NASDAQ:AMRN) by 16.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 240,020 shares of the biopharmaceutical company’s stock after selling 46,600 shares during the period. Cutter & CO Brokerage Inc. owned 0.06% of Amarin worth $118,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Waterfront Wealth Inc. grew its stake in Amarin by 181.4% in the 4th quarter. Waterfront Wealth Inc. now owns 2,481,766 shares of the biopharmaceutical company’s stock valued at $1,204,000 after buying an additional 1,599,956 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in shares of Amarin in the fourth quarter valued at about $68,000. LCM Capital Management Inc increased its stake in shares of Amarin by 3.1% in the fourth quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company’s stock worth $407,000 after purchasing an additional 25,100 shares during the period. Arkfeld Wealth Strategies L.L.C. lifted its position in shares of Amarin by 52.6% during the 4th quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 20,000 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Amarin by 8.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company’s stock valued at $816,000 after purchasing an additional 104,939 shares during the period. Institutional investors own 22.25% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded Amarin from a “hold” rating to a “sell” rating in a research report on Tuesday.

Amarin Trading Down 1.1 %

Shares of AMRN stock opened at $0.57 on Thursday. The firm has a market capitalization of $234.95 million, a P/E ratio of -6.36 and a beta of 1.83. Amarin Co. plc has a 1 year low of $0.43 and a 1 year high of $1.36. The firm’s fifty day simple moving average is $0.55 and its 200 day simple moving average is $0.56.

Amarin Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.